| Previous Close | 0.8800 |
| Open | 0.8300 |
| Bid | 0.8500 x 0 |
| Ask | 0.9100 x 0 |
| Day's Range | 0.8300 - 0.9100 |
| 52 Week Range | 0.1250 - 1.0400 |
| Volume | 11,135 |
| Avg. Volume | 44,740 |
| Market Cap | 50.423M |
| Beta (5Y Monthly) | 1.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Aurora Spine Corporation Announces Successful Launch of its Proprietary SiLO™ Posterior SI Joint Fusion System
Company publishes biomechanical whitepaper on the superior placement of the SiLO graftCARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it has successfully launched its proprietary SiLOTM Posterior SI Joint Fusion System (SiLO), which was designed specifically for posterior sacroiliac joint fusion. Sacroiliac joint (SI Joint) fusion is a surgical procedure which fuses the iliac bone (pelvis) to the spine (sacrum) for stabilization. The SiLOTM Posterior SI Joint Fusion System is a single graft Posterior SI-Fusion System made of human cortical bone and was developed to provide a simple, safe, and reproducible method of stabilizing and fusing the sacroiliac joint. The SiLO graft was designed specifically for posterior sacroiliac joint fusions and consists of three levels of ridges along its circumferential solid body to increase implant retention and stability through its unique “Dowel Anchorage Design.” The SiLO graft is shaped for enhanced 360-degree bone incorporation and includes vertical side-channels that allow for additional bone graft material during insertion for enhanced stability. The SiLO graft is implanted with custom designed, patent pending instrumentation. Trent Northcutt, President and Chief Executive Officer of Aurora Spine, commented, “We are pleased with the recent commercial launch of Aurora’s proprietary SiLOTM Posterior SI Joint Fusion System, which we expect to be a key growth driver for Aurora into a market that has gained acceptance among key surgeons and pain interventionalists alike. Also, conducting SI Joint Fusion posteriorly is a procedure that is expected to grow immensely in the coming years, as it can be done through minimally invasive surgery (MIS) and has quicker recovery times for patients.” In a recent BONEZONE article titled “SI Joint Fusion Market Has Rapid Growth Potential” author Mike Evers wrote, “Minimally invasive sacroiliac (SI) joint fusion is an increasingly common treatment for patients with low back pain due to SI joint dysfunction. Therefore, it represents a high-growth potential niche in the orthopedic spine market.” The article goes on to state, “…we see the market growing significantly in the medium-term once surgical volumes normalize to pre-COVID levels. The 2019 SI joint fusion market ranged between $150 million to $250 million globally, with double-digit annual growth according to our estimates.”1 Technical Summary In conjunction with the launch, the company issued a cadaver-based biomechanical investigation whitepaper on the performance of the SiLO graft, which is circular, against a rectangular-shaped graft. The rectangular-shaped graft was placed in the left sacroiliac joint and tested. The SiLO graft was placed in the right sacroiliac joint and tested. The experiment was conducted in a cadaver-based multi-directional bending model. The results showed that the SiLO graft immobilized the sacroiliac joint at the graft site and was more effective at doing so because it interlocks with the sacral and iliac bones. The SiLO graft also had a more effective interlock because it is larger, and its round reamer cuts a precise, highly congruent channel. In addition, the flexion-extension centers were located posterior and caudal to the joints in the intact samples. The centers of motion moved towards the location of the grafts for both the SiLO graft placement and the rectangular-shaped graft placement. The center of motion moved directly over the SiLO graft after placement, which is optimal for bony fusion; while the center of motion failed to move over the rectangular-shaped graft, indicating less effective fixation. Laszlo Garamszegi, Chief Technology Officer and Aurora Spine, added, “We are also happy to share the results of the work conducted by industry professionals and Aurora’s engineering team in our recent biomechanical whitepaper, which had very positive results. Part of the exercise was to test the simplicity of applying the SiLO to the sacroiliac joint, but at the same time were also able to see how its ability to be precisely placed performs against a more traditional SI Joint Fusion graft. The SiLO performed extremely well during the testing and we look forward to sharing this data with surgeons and pain interventionalists.” To access the whitepaper in its entirety, go to: https://aurorapaincare.com/s/F220149_A-SILO-Biomechanics-Whitepaper.pdf. About Aurora Spine Aurora Spine is focused on bringing new solutions to the spinal implant and pain management markets through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances. 1For the full article: https://www.bonezonepub.com/2770-si-joint-fusion-market-has-rapid-growth-potential Contact: Aurora Spine Corporation Trent NorthcuttPresident and Chief Executive Officer(760) 424-2004 Chad ClouseChief Financial Officer(760) 424-2004www.aurora-spine.com Adam LowensteinerLYTHAM PARTNERS, LLCPhoenix | New YorkTelephone: 646-829-9700ASAPF@lythampartners.com
- GlobeNewswire
Aurora Spine Announces Receipt of Loan Proceeds Under Paycheck Protection Program
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSX VENTURE:ASG) (OTCQB:ASAPF) announced today that it has received loan proceeds of $350,140 (“PPP Loan”) under the Second Draw Paycheck Protection Program. The Paycheck Protection Program (“PPP”) was established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) in order to enable small businesses to pay employees during the coronavirus crisis and provides loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the PPP is eligible to be forgiven provided that the borrower uses the loan proceeds during the eight week or 24 week period after receiving them and provided that the proceeds are used for payroll costs (including benefits), rent, mortgage interest, utility costs and worker protection costs related to COVID-19. Principal and interest payments on any unforgiven portion of the PPP Loan will be deferred for ten months and will accrue interest at a fixed annual rate of 1%. Additionally, the remaining PPP Loan balance will carry a five-year maturity date. There is no prepayment penalty on the PPP Loan. About Aurora Spine Aurora Spine is focused on bringing new solutions to the spinal implant and pain management markets through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the PPP Loan and its potential forgiveness or repayment. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances. For more information, please contact: Aurora Spine Corporation Trent Northcutt President and Chief Executive Officer(760) 424-2004 Chad Clouse Chief Financial Officer (760) 424-2004 www.aurora-spine.com Adam Lowensteiner LYTHAM PARTNERS, LLCPhoenix | New YorkTelephone: 646-829-9700arosf@lythampartners.com
- GlobeNewswire
Aurora Spine Announces Listing of Shares to OTCQB Exchange
- New Listing to improve shareholder outreach in US - CARLSBAD, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that its common shares are now trading on the OTCQB Venture Market (the "OTCQB Venture"), a US trading platform that is operated by the OTC Markets Group in New York. The Company will trade on the OTCQB Venture under symbol "ASAPF" (links to http://www.otcmarkets.com/stock/ASAPF/quote); the Company's common shares will continue to trade on the TSX Venture Exchange under the symbol "ASG". Aurora Spine trades on the OTCQB® Venture Market for early-stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com. “We are pleased to list Aurora Spine shares on the OTCQB Venture Market,” said Trent J. Northcutt, President and CEO of Aurora Spine. “This move will allow Aurora Spine to improve its status as a publicly traded company by now enabling US-based investors to seamlessly get involved in Aurora. We believe this new listing will also assist us in our investor awareness program in the US, which we embarked on during 2020 and add credibility and transparency among our customers, physicians and patients that use Aurora Spine products.” Mr. Northcutt added, “This listing is very timely for Aurora Spine as we embark on continued growth by focusing on developing and selling more proprietary products. We have several new product launches slated in 2021 and look forward to sharing those announcements with investors as they evolve.” About Aurora Spine Aurora Spine is focused on bringing new solutions to the spinal implant and pain management markets through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances. Contact: Aurora Spine Corporation Trent NorthcuttPresident and Chief Executive Officer(760) 424-2004 Chad ClouseChief Financial Officer(760) 424-2004www.aurora-spine.comwww.aurorapaincare.com Adam LowensteinerLYTHAM PARTNERS, LLCPhoenix | New YorkTelephone: 646-829-9700arosf@lythampartners.com
